Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:53:17 EDT Tue 01 Jul 2025
Enter Symbol
or Name
USA
CA



Q:CRNX - CRINETICS PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CRNX - Q0.128.30·32.020.128.43-0.33-1.1556.315,3997,82628.75  29.239  28.3462.53  24.1019:36:44Jun 3015 min RT 2¢

Recent Trades - Last 10 of 7826
Time ETExPriceChangeVolume
19:36:44Q28.40-0.36199
19:19:47Q28.55-0.212
16:46:00Q28.43-0.33409
16:20:00Q28.43-0.33106
16:04:14Q28.43-0.331
16:04:13Q28.43-0.331
16:04:13Q28.43-0.331
16:04:12Q28.43-0.331
16:04:04Q28.43-0.331
16:02:44Q28.43-0.333,572

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-30 16:05U:CRNXNews ReleaseCrinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
2025-06-16 08:00U:CRNXNews ReleaseCrinetics Pharmaceuticals to Host R&D Day on June 26, 2025
2025-06-10 16:30U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-23 08:00U:CRNXNews ReleaseCrinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
2025-05-15 16:05U:CRNXNews ReleaseCrinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
2025-05-12 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-08 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
2025-04-11 08:00U:CRNXNews ReleaseCrinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
2025-04-10 17:04U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-27 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
2025-03-10 16:36U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-27 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-02-24 08:30U:CRNXNews ReleaseCrinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
2025-02-20 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
2025-02-10 16:44U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-06 16:35U:CRNXNews ReleaseCrinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
2025-01-10 17:15U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-10 07:00U:CRNXNews ReleaseCrinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
2025-01-06 08:00U:CRNXNews ReleaseCrinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-16 08:00U:CRNXNews ReleaseCrinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer